• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Rezolute Inc. (Amendment)

    2/13/24 5:00:07 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RZLT alert in real time by email
    SC 13G/A 1 ea193546-13ga1vivo_rezolute.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1 )*

     

    Rezolute, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    76200L309

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

       

    1.

    NAMES OF REPORTING PERSONS

     

    Vivo Opportunity Fund Holdings, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☐

    (b) þ

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    3,242,842 (1)

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    3,242,842 (1)

    8.

    SHARED DISPOSITIVE POWER

     

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,242,842 (1)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES      ☐

     

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    8.2% (2)

    12.

    TYPE OF REPORTING PERSON

     

    PN

     

    (1)The number represents shares of common stock, $0.001 par value (the “Common Stock”) of Rezolute, Inc. (the “Issuer”) held of record by Vivo Opportunity Fund Holdings, L.P, as of December 31, 2023. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

     

    (2)Based on 39,625,271 shares of Common Stock outstanding of the Issuer as of November 10, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the “SEC”) on November 13, 2023.

     

    2

     

     

    1.

    NAMES OF REPORTING PERSONS

     

    Vivo Opportunity, LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☐

    (b) þ

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    3,242,842 (1)

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    3,242,842 (1)

    8.

    SHARED DISPOSITIVE POWER

     

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,242,842 (1)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES      ☐

     

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    8.2% (2)

    12.

    TYPE OF REPORTING PERSON

     

    OO

     

    (1)

    The number represents shares of Common Stock of the Issuer held of record by Vivo Opportunity Fund Holdings, L.P, as of December 31, 2023. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

     

    (2)

    Based on 39,625,271 shares of Common Stock outstanding of the Issuer as of November 10, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q, filed with the SEC on November 13, 2023.

     

    3

     

     

    Item 1. (a) Name of Issuer:

     

    Rezolute, Inc. (the “Issuer”)

     

      (b) Address of Issuer’s Principal Executive Offices:

     

    275 Shoreline Drive, Suite 500, Redwood City, CA 94065 

     

    Item 2. (a) Name of Person Filing:

     

    (i)      Vivo Opportunity Fund Holdings, L.P.

     

    (ii)     Vivo Opportunity, LLC

     

      (b) Address of Principal Business Office or, if None, Residence:

     

    192 Lytton Avenue, Palo Alto, CA 94301

     

      (c) Citizenship:

     

    (i)      Vivo Opportunity Fund Holdings, L.P., a Delaware limited partnership; and

     

    (ii)     Vivo Opportunity, LLC, a Delaware limited liability company. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

     

      (d) Title of Class of Securities:

     

    Common Stock, par value $0.001 per share

     

      (e) CUSIP Number:

     

    76200L309

     

    Item 3. If This Statement is Filed Pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

     

      (a) ☐ Broker or dealer registered under Section 15 of the Act.
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act.
           
      (c) ☐  Insurance company as defined in Section 3(a)(19) of the Act.
           
      (d) ☐  Investment company registered under Section 8 of the Investment Company Act of 1940.
           
      (e) ☐  An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) ☐  An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) ☐  A parent holding company or control person in accordance with § 240.13d-1(b)(l)(ii)(G);
           
      (h) ☐  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
           
      (i) ☐  A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
           
      (j) ☐  A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
           
      (k) ☐  Group, in accordance with § 240.13d-1(b)(l)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1(ii)(j), please specify the type of institution: ________________

     

    Not Applicable.

     

    4

     

     

    Item 4. Ownership.

     

      (a) Amount Beneficially Owned:

     

    All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

     

      (b) Percent of class:

     

    8.2%

     

      (c) Number of shares as to which such person has:

     

      (i) Sole power to vote or to direct the vote:  3,242,842

     

      (ii) Shared power to vote or to direct the vote: 0

     

      (iii) Sole power to dispose or to direct the disposition of:  3,242,842      

     

      (iv) Shared power to dispose of or to direct the disposition of: 0

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a11.

     

    5

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 13, 2024

     

    Vivo Opportunity Fund Holdings, L.P.

     

    By: Vivo Opportunity, LLC, its General Partner

     

    /s/ Kevin Dai

     
    Name: Kevin Dai  
    Title:   Managing Member  

     

    Vivo Opportunity, LLC

     

    /s/ Kevin Dai

     
    Name: Kevin Dai  
    Title:   Managing Member  

     

     

    6

     

    Get the next $RZLT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RZLT

    DatePrice TargetRatingAnalyst
    11/5/2024$12.00Outperform
    Wedbush
    8/27/2024$11.00Buy
    Guggenheim
    7/17/2024$13.00Buy
    BTIG Research
    6/4/2024$14.00Buy
    Craig Hallum
    4/9/2024$8.00Buy
    Maxim Group
    8/2/2022$17.00Buy
    Canaccord Genuity
    6/15/2022$9.00Overweight
    Cantor Fitzgerald
    11/29/2021$30.00 → $17.00Buy
    Canaccord Genuity
    More analyst ratings

    $RZLT
    Leadership Updates

    Live Leadership Updates

    See more
    • Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

      REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, announced the appointment of Erik Harris to its Board of Directors, effective immediately. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings more than 20 years of biopharmaceutical expertise to Rezolute. "We are thrilled to welcome Erik to our board. He is a recognized rare disease commercial expert, and his insights will be invaluable as we advance our lead programs through clinical development and prepare for p

      3/26/25 7:30:00 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer

      REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the addition of Daron Evans, MS, MBA, to its leadership team as Chief Financial Officer as well as the grant of share options as a material inducement for his appointment (the "Inducement Grant"). About Mr. Evans "This is a pivotal year for Rezolute as we initiated our Phase 3 clinical study for RZ358 in congenital hyperinsulinism and anticipate reporting topline data from our Phase 2 study for RZ402 in diabetic macular edema in the secon

      1/24/24 8:00:00 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute's Oral PKI for Treatment of DME

      REDWOOD CITY, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced that the Company has initiated dosing in a Phase 1b multiple-ascending dose study of RZ402, Rezolute's investigational oral plasma kallikrein inhibitor (PKI) for the treatment of diabetic macular edema (DME). Rezolute also announced the appointment of ophthalmology expert and key opinion leader, Dr. Rajat Agrawal, MD, MS, as Vice President, Clinical Development to lead the RZ402 clinical development program. "The Phase 1b study will evaluate the

      8/10/21 7:00:00 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wedbush initiated coverage on Rezolute with a new price target

      Wedbush initiated coverage of Rezolute with a rating of Outperform and set a new price target of $12.00

      11/5/24 6:25:51 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Rezolute with a new price target

      Guggenheim initiated coverage of Rezolute with a rating of Buy and set a new price target of $11.00

      8/27/24 7:36:43 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Rezolute with a new price target

      BTIG Research initiated coverage of Rezolute with a rating of Buy and set a new price target of $13.00

      7/17/24 7:55:53 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    Financials

    Live finance-specific insights

    See more
    • Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

      Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Benefit shown in individual patient cases with RZ358 for tumor-associated hyperinsulinism (taHI) under Expanded Access Program (EAP); drives alignment with FDA on unmet need and potential to move into late-stage clinical development to further evaluate RZ358 in this population REDWOOD CITY, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial re

      2/13/24 4:05:00 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Reports First Quarter Fiscal 2024 Results

      REDWOOD CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial results for the first quarter of fiscal 2024 ended September 30, 2023. "We are on track to commence our Phase 3 study for RZ358 to treat congenital hyperinsulinism prior to year-end and are delighted to have recently obtained PRIME eligibility from the European Medicines Agency for this indication," said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. "We also anticipate completing enrollment this quarter for our o

      11/13/23 4:05:00 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

      REDWOOD CITY, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt treatment paradigms for devastating metabolic diseases, today announced its financial results for the fourth quarter and full fiscal year ended June 30, 2023. "We are delighted that we are poised to initiate sunRIZE – our Phase 3 study of RZ358, which we hope will bring us one step closer to making this therapy available to patients and their families suffering from congenital hyperinsulinism. We are also anticipating results from our Phase 2 study of RZ402 in the first quarter of 20

      9/14/23 4:05:00 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hogenhuis Wladimir bought $19,733 worth of shares (6,758 units at $2.92), increasing direct ownership by 9% to 84,025 units (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      4/1/25 3:52:55 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Elam Nevan C bought $34,999 worth of shares (12,302 units at $2.85), increasing direct ownership by 6% to 224,119 units (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      3/31/25 9:18:52 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Evans Daron bought $57,700 worth of shares (20,000 units at $2.88), increasing direct ownership by 4% to 237,900 units (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      3/28/25 8:40:13 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

      Registrational study in patients with tumor hyperinsulinism (HI) expected to commence mid-year Designation underscores need for therapies to treat severe hypoglycemia in the oncology setting REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by HI, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its investigational therapy, ersodetug, for the treatment of hypoglycemia caused by tumor HI.  BTD for ersodetug was granted based on clinical trial data across the overall program and a re

      5/5/25 8:00:00 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute to Participate in Upcoming Investor Conferences

      REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences: Event: The Citizens JMP Life Sciences Conference Date: May 7-8, 2025 Event: H.C. Wainwright BioConnect Investor Conference Date: May 20, 2025 Event: Craig-Hallum Institutional Investor Conference Date: May 28, 2025 Event: Jefferies Global Healthcare Conference Date: June 3-5, 2025 Management will be participating in one-on-one investor meetings thro

      5/1/25 8:00:00 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute, Inc. Announces Closing of Underwritten Offering

      NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the closing of its previously announced underwritten offering (the "Offering") of an aggregate of 24,940,769 shares of its common stock at an offering price of $3.25 per share, which includes 4,153,846 shares of common stock pursuant to the exercise in full of the underwriters' option to purchase additional shares of common stock and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 6,905,385 shares of common stock a

      4/25/25 4:30:35 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    SEC Filings

    See more
    • Rezolute Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Rezolute, Inc. (0001509261) (Filer)

      4/28/25 5:00:44 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Rezolute, Inc. (0001509261) (Filer)

      4/23/25 5:22:25 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Rezolute Inc.

      424B5 - Rezolute, Inc. (0001509261) (Filer)

      4/23/25 5:20:21 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

      SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

      11/14/24 6:59:50 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

      SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

      11/14/24 10:04:23 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

      SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

      11/13/24 5:31:40 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hogenhuis Wladimir bought $19,733 worth of shares (6,758 units at $2.92), increasing direct ownership by 9% to 84,025 units (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      4/1/25 3:52:55 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Elam Nevan C bought $34,999 worth of shares (12,302 units at $2.85), increasing direct ownership by 6% to 224,119 units (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      3/31/25 9:18:52 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Evans Daron bought $57,700 worth of shares (20,000 units at $2.88), increasing direct ownership by 4% to 237,900 units (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      3/28/25 8:40:13 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care